ReviewHuman immunology2021
Review of the immune mechanisms of preeclampsia and the potential of immune modulating therapy.
Review in Human immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis.American journal of obstetrics and gynecology · 2022Pooled it
- Maternal-fetal immune conflict contributes to male-specific impairments in a mouse model of neurodevelopmental disorders.Science advances · 2026Article
- Narrative Review on Therapies That Influence Inflammatory Responses During Extremely Premature Perinatal Respiratory Transition.Acta paediatrica (Oslo, Norway : 1992) · 2026Review
- The Immuno-Cardiovascular Storm of Pre-Eclampsia: Cytokine-Mediated Endothelial Injury, Thrombosis, and Maternal Cardiovascular Instability.Comprehensive Physiology · 2026Review
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- Understanding Preeclampsia: Integrating Placental Dysfunction, Immune Dysregulation and microRNA-Mediated Epigenetic Regulation.International journal of molecular sciences · 2026Review
- The signature of pyroptosis-related gene diagnosis and immune microenvironment in preeclampsia.BMC pregnancy and childbirth · 2026Article
- Immune profiling-informed immunomodulation associated with gestational extension in early-onset preeclampsia with monochorionic twins: a case report.Frontiers in immunology · 2026Article
- Role of PD-L1 in the Pathogenesis of Pre-Eclampsia and Its Association with Adverse Fetal Outcomes.Turk patoloji dergisi · 2026Article
- Regulatory T cells in human pregnancy: mechanisms, dysregulation, and therapeutic perspectives.Frontiers in immunology · 2026Review
- A cross-sectional examination of immune adaptations during pregnancy in the ECHO Cohort.Frontiers in immunology · 2026Article
- Integrative Transcriptomic and Network Pharmacology Analysis Suggests Potential Mechanisms of Propofol in Early-Onset Preeclampsia.International journal of women's health · 2026Article
- Article
- The Clinical Implications of Progesterone in Preeclampsia.Biomolecules · 2025Review
- Molecular profiles of the great obstetrical syndromes reveal common features and dynamic changes in early pregnancy.Communications medicine · 2025Article
- Regulatory KIRScience translational medicine · 2025Article
- Hypertensive Disorders of Pregnancy, Preterm Delivery, and Infant Size: Which Mothers Have Highest Cardiovascular Disease Mortality?Paediatric and perinatal epidemiology · 2025Article
- Linking TLR-7 Signaling to Downregulation of Placental P-Glycoprotein: Implications for Fetal Drug Exposure.Pharmaceutics · 2025Article
- Molecular subtyping of hypertensive disorders of pregnancy.Nature communications · 2025Article
- Organ development in growth-restricted fetuses in the reduced uterine perfusion pressure rat model: A vascular approach of brain, heart, and kidney.Physiological reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Successful pregnancy relies on maternal immunologic tolerance mechanisms limit maladaptive immune responses against the semi-allogeneic fetus and placenta and support fetal growth. Preeclampsia is a common disorder of pregnancy that affects 4-10% of pregnancies and is a leading cause of maternal and neonatal morbidity and mortality. Preeclampsia clinically manifests as maternal hypertension, proteinuria, and progressive multi-organ injury likely triggered by hypoxic injury to the placenta, resulting in local and systemic anti-angiogenic and inflammatory factor production. Despite the steady rising rates of preeclampsia in the United States, effective treatment options are limited to delivery, which improves maternal status often at the cost of prematurity in the newborn. Preeclampsia also increases the lifelong risk of cardiovascular disease for both mother and infant. Thus, identifying new therapeutic targets is a high priority area to improve maternal, fetal, and infant health outcomes. Immune abnormalities in the placenta and in the maternal circulation have been reported to precede the clinical onset of disease. In particular, excessive systemic and placental complement activation and impaired adaptive T cell tolerance with Th1/Th2/Th17/Treg imbalance has been reported in humans and in animal models of preeclampsia. In this review, we focus on the evidence for the immune origins of preeclampsia, discuss the promise of immune modulating therapy for prevention or treatment, and highlight key areas for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.